| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
IMP Stock Overview
Imexpharm Corporation manufactures, processes, trades, imports, and exports pharmaceutical products in Vietnam and internationally.
Rewards
Risk Analysis
No risks detected for IMP from our risk checks.
Imexpharm Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₫62,100.00 |
| 52 Week High | ₫86,400.00 |
| 52 Week Low | ₫57,000.00 |
| Beta | 0.43 |
| 1 Month Change | -4.17% |
| 3 Month Change | -5.91% |
| 1 Year Change | -10.26% |
| 3 Year Change | 68.54% |
| 5 Year Change | 35.93% |
| Change since IPO | 27.65% |
Recent News & Updates
Shareholder Returns
| IMP | VN Pharmaceuticals | VN Market | |
|---|---|---|---|
| 7D | 1.6% | -0.03% | 0.9% |
| 1Y | -10.3% | -3.6% | -8.1% |
Return vs Industry: IMP underperformed the VN Pharmaceuticals industry which returned -3.6% over the past year.
Return vs Market: IMP underperformed the VN Market which returned -8.1% over the past year.
Price Volatility
| IMP volatility | |
|---|---|
| IMP Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in VN Market | 9.6% |
| 10% least volatile stocks in VN Market | 3.8% |
Stable Share Price: IMP is not significantly more volatile than the rest of VN stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: IMP's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1977 | 1,225 | Dao Tran | https://www.imexpharm.com |
Imexpharm Corporation manufactures, processes, trades, imports, and exports pharmaceutical products in Vietnam and internationally. The company’s products include oral and injectable antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-histamines, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals. It is also involved in the import and export of medical equipment and supplies, chemicals, materials for medicine manufacturing and packaging, and chemicals used for sterilization or disinfection in humans.
Imexpharm Corporation Fundamentals Summary
| IMP fundamental statistics | |
|---|---|
| Market Cap | ₫4.14t |
| Earnings (TTM) | ₫176.27b |
| Revenue (TTM) | ₫1.32t |
23.5x
P/E Ratio3.1x
P/S RatioIs IMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMP income statement (TTM) | |
|---|---|
| Revenue | ₫1.32t |
| Cost of Revenue | ₫696.03b |
| Gross Profit | ₫625.40b |
| Other Expenses | ₫449.14b |
| Earnings | ₫176.27b |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.64k |
| Gross Margin | 47.33% |
| Net Profit Margin | 13.34% |
| Debt/Equity Ratio | 5.3% |
How did IMP perform over the long term?
See historical performance and comparison